THERAPEUTIC APPROACHES TO THE PROBLEM of diabetic angiopathy in diabetes MELLITUS TYPE 2: FOCUS ON OPPORTUNITIES OF TRICOR


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The literature review examines approaches to the treatment of diabetic angiopathy. The macroangiopathies multifactorial therapy often overlooke feature of diabetic dyslipidemia - hypertriglyceridemia. The positive effect of carbohydrate control for all microangiopathy proved. On the other hand the effectiveness of the blood pressure control and statin therapy proved for nephropathy only. The review analyzes pathogenetic features of the diabetic microvascular complications reduction in the FIELD study in response to therapy with fenofibrate. The possibilities of the drug in the treatment of diabetic vascular complications considered except its effect on hypertriglyceridemia.

Full Text

Restricted Access

About the authors

Lyudmila Aleksandrovna Ruyatkina

Novosibirsk State Medical University

Email: larut@list.ru
MD, professor, Department of emergency therapy with endocrinology and occupational diseases of the faculty of advanced training and professional retraining of doctors 630091, Novosibirsk, 52 Krasny prospect

Dmitry Segreevich Ruyatkin

Novosibirsk State Medical University

Email: dr79@mail.ru
PhD, associate professor of Department of emergency therapy with endocrinology and occupational diseases of the faculty of advanced training and professional retraining of doctors 630091, Novosibirsk, 52 Krasny prospect

Svetlana Andreevna Zemlyanukhina

Polyclinic № 2 of Non-state healthcare institution «Road clinical hospital at the station Novosibirsk-Main JSC «RZD»»

Email: svetlana7@211.ru
endocrinologist 630123, Novosibirsk, 21 Sibirskaya St

References

  1. Hess K., Marx N., Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. Eur. Heart J. 2012;14:4-13.
  2. Шестакова М.В., Лепетухин А.Е., Кварацхелия М.В., Рожинская Л.Я., Андрусев A.M., Кирхман В.В., Томилина Н.А., Дедов И.И. Ведение больных сахарным диабетом с терминальной хронической почечной недостаточностью на диализе: методические указания № 2004/38. М., 2004. 40 с.
  3. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Национальные рекомендации. Клиническая фармакология и терапия. 2014;23(3):4-27
  4. Руяткина Л.А., Яхонтов Д.А., Ахмерова Е.В. Функциональное состояние почек и эндотелийзависимая вазодилатация при артериальной гипертонии в сочетании с сахарным диабетом 2 типа. Медицина и образование в Сибири. 2014;2
  5. Lee W.J., Sobrin L., Kang M.H., Seong M., Kim Y.J., Yi J.H., Miller J.W., Cho H.Y. Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye (Lond). 2014;28(9):1119-25.
  6. Sj0lie A.K., Dodson P., Hobbs F.R. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int. J. Clin. Pract. 2011:65(2) :148-53.
  7. Nielsen S.F., Nordestgaard B.G. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014:2(11) :894-900.
  8. Tesfaye S. Diabetic neuropathy: new insights with professor Solomon Tesfaye [internet]. Medscape diabetes & endocrinology; [cited 2014 September 23]. Available from: http://www.medscape.com/viewarticle/832167
  9. Дедов И.И., Шестакова М.В., Галстян Г.Р. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 7-й выпуск. Сахарный диабет. 2015;18(1 S).
  10. Gubitosi-Klug R.A. The diabetes control and complications tria. Epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care. 2014;37(1):44-9.
  11. Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst. Rev. 2012;6:CD007543.
  12. Tucker M.E. Novel eye measure finds neuropathy in prediabetes [internet]. Medscape Medical News; [cited 2014 July 09]. Available from: http://www.medscape.com/viewarticle/828016
  13. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Medicine. 2009:10(2):393-400.
  14. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., Ionescu-Tirgoviste C., Witte D.R., Fuller J.H. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 2005;352:341-50.
  15. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H., Pedersen O. Multi-factorial interventions and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348(5):383-93.
  16. Subedi B.H. The role of statins in diabetes treatment. Diabetes spectrum. 2013;26(3):156-64.
  17. Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., Polonsky K.S. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47(3):358-64.
  18. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995;44(8):863-70.
  19. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr. Rev. 2008;29(3):351-66.
  20. Tenenbaum A., Klempfner R., Fisman E.Z. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc. Diabetol. 2014;13(1 ) :159.
  21. Robertson R.P., Harmon J., Tran P.O., Poitout V. ß-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53 (Suppl 1):S119-24.
  22. Li N., Frigerio F., Maechler P. The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress. Biochem. Soc. Trans. 2008;36(Pt 5):930-4.
  23. Tomlinson D.R., Gardiner N.J. Glucose neurotoxicity. Nat. Rev. Neurosci. 2008;9(1):36-45.
  24. Padilla A., Descorbeth M., Almeyda A.L., Payne K., De Leon M. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res. 2011;1370:64-79.
  25. Cermenati G., Abbiati F., Cermenati S., Brioschi E., Volonterio A., Cavaletti G., Saez E., De Fabiani E., Crestani M., Garcia-Segura L.M., Melcangi R.C., Caruso D., Mitro N. Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. J. Lipid. Res. 2012;53(2):300-10.
  26. Xu L., Tang D., Guan M., Xie C., Xue Y. Effect of high-fat diet on peripheral neu-ropathy in C57BL/6 mice. Int. J. Endocrinol. 2014;2014:305205.
  27. Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M.R., Groop L. The metabolic syndrome in-fluences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001 ;44(9):1148-54.
  28. Wiggin T.D., Sullivan K.A., Pop-Busui R.T., Amato A., Sima A.A., Feldman E.L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634-40.
  29. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesäniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61.
  30. Аметов А.С., Лысенко М.А. Роль и место фенофибрата в комплексной многофакторной терапии диабетической периферической нейропатии при сахарном диабете типа 2. Эндокринология. 2013:3.
  31. Демидова Т.Ю., Трахтенберг Ю.А. Современные возможности терапии диабетической ретинопатии. Сахарный диабет. 2014;3:122-8
  32. Коненков В.И., Климонтов В.В. Ангиогенез и васкулогенез при сахарном диабете: новые концепции патогенеза и лечения сосудистых осложнений. Cахарный диабет. 2012;4:17-27
  33. Osaadon P., Fagan X.J., Lifshitz T., Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye. 2014;28(5):510-20.
  34. Panigrahy D., Kaipainen A., Huang S., Butterfield C.E., Barnés C.M., Fannon M., Laforme A.M., Chaponis D.M., Folkman J., Kieran M.W. PPAR alpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci. USA. 2008;105(3):985-90.
  35. Chen N.Y., Hu Y., Lin M., Jenkins A.J., Keech A.C., Mott R., Lyons T.J., Ma J.X. Therapeutic effects of PPARa agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62(1):261 -72.
  36. Salehi E., Khazaei M., Rashidi B. Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats. Gen. Physiol. Biophys. 2012;31(3):255-60.
  37. Salehi E., Khazaei M. Fenofibrate, a peroxisome proliferator-activated receptor alpha, improves myocardial capillary density in diabetic rats. J. Pak. Med. Assoc. 2012;62(3 Suppl 2):S9-12.
  38. Soares R. Angiogenesis in diabetes. Unraveling the angiogenic paradox. Open Circ. J. 2010;3(2):3-9.
  39. Ginsberg H.N., Illingworth D.R. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am. J. Cardiol. 2001;88(6A):9H-15H.
  40. Jagla A., Schrezenmeir J. Postprandial triglycerides and endothelial function. Exp. Clin. Endocrinol. Diabetes. 2001 ;109(4) :S533-47.
  41. Meilin E., Aviram M., Hayek T. Insulin increases macrophage triglyceride accumulation under diabetic conditions through the down regulation of hormone sensitive lipase and adipose triglyceride lipase. Biofactors. 2011 ;37(2):95-103.
  42. Александров А.А. Сахарный диабет: болезнь «взрывающихся» бляшек. Consilium Medicum. 2001;1:4-10.
  43. Silveira A. Postprandial triglycerides and blood coagulation. Exp. Clin. Endocrinol. Diabetes. 2001 ;109(4) :S527-32.
  44. Стаценко М.Е., Туркина С.В., Толстов С.Н. Место p-FOX-ингибиторов свободных жирных кислот в комбинированной терапии сердечно-сосудистых осложнений у больных сахарным диабетом 2 типа. Российский кардиологический журнал. 2011 ;2(88):102-10.
  45. Cavallero E., Piolot A., Jacotot B. Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects. Diabete Metab. 1995;21(2):118-20.
  46. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67(1):121-53.
  47. Keating G.M. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am. J. Cardiovasc. Drugs. 2011 ;11 (4):227-47.
  48. Tenenbaum A., Fisman E.Z. If it ain't broke, don't fix it: a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc. Diabetol. 2010;9:24.
  49. Кошель Л.В., Романцова Т.И. Роль фенофибрата в лечении микрососудистых осложнений сахарного диабете 2 типа. Сахарный диабет. 2009;4:99-103.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies